

# **NIH StrokeNet Meeting**

### 3-June, 2014 10:00 am – 4:00 pm Crystal Gateway Marriott







## Welcome

- Brief Agenda Overview
  - Specific Ongoing Trials/Studies
    - MISTE III
    - CREST 2
    - I DEF
    - PCORI
    - Existing SPOTRIAS Trials
  - Working Lunch with Q and A
  - Educational Core Update
  - StrokeNet WebDCU Orientation
  - Breakouts for Educational Core, and Working Group discussions



# National Data Management Center

- Yuko Palesch
- Wenle Zhao
- Catherine Dillon
- Jessica Simons
- Jordan Elm
- Renee Martin
- Sharon Yeatts
- Jaemyung Kim



- May 14, 2014: U01 Funding Announcement for the network published.PAR-14-220: <u>NIH StrokeNet Clinical Trials and Biomarker</u> Studies for Stroke Treatment, Recovery, and Prevention (U01)
- X01 (the company companion mechanism) (pending)
- SBIR (Small Business) (pending)



Specific Ongoing Trials/Studies Presentations and Q and A

# **Ongoing SPOTRIAS Trials**

- STOP-IT
- CLEAR-FDR
- DESERVE
- ARTSS-2
- MR-WITNESS
- NeuStart Phase 2
- ICTUS 2



# STOP-IT: Study Hypotheses


- Confirm in a prospective study:
  - Sensitivity and specificity of CTA spot sign for hematoma growth
- Determine:
  - Feasibility of CTA to identify ICH patients at high risk of hematoma growth and select patients for randomization to treatment with rFVIIa or placebo
- Randomize ICH patients presenting within five hours of onset with a spot sign to treatment with rFVIIa, at 80 μg/kg vs placebo to:
  - Determine if rFVIIa is effective at reducing hematoma growth among patients with a spot sign
  - Provide preliminary efficacy data for treatment paradigm



# STOP-IT Study Design

- Treatment criteria\*
  - Age 18-80 years
  - Baseline CT within 5 hours from onset
  - ICH volume 0.5 90 cc
  - GCS > 8 at presentation
  - Pre-admission mRS score < 2
  - No prior thromboembolic history
  - Baseline troponin WNL
  - For spot positive patients, dosing of study drug within 90 minutes of enrolling CT scan
- Not looking for additional sites (limited medication supply)
- Matt Flaherty, Pl

\*Partial list



### **CLEAR-FDR**: Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke-Full Dose Regimen

 Primary objective - estimate sICH rate in AIS patients treated with rt-PA (0.9mg/kg) within 3 hours of symptom onset plus eptifibatide (bolus 135 mcg/kg and 2 hour infusion at 0.75 mcg/kg/min)

• Design – single arm, prospective open label study



## **CLEAR-FDR**

- Stopping Rules Enroll up to 30 patients; stop if 3 sICH cases within the first 19 patients or 4 sICH cases within 29 patients (i.e., sICH rate ~>8%)
- Inclusion age 18-85, NIHSS  $\geq 6$
- 12 of 30 cases enrolled to date
- Not currently planning on recruiting additional sites
- Dr. Adeoye Pl



# DESERVE Trial : Discharge Educational Strategies for Reduction of Vascular Events

#### Specific Aims

To evaluate the effectiveness of an innovative multi-level discharge intervention (skills, chronic care model, bilingual research health workers) versus standard discharge care on vascular risk reduction (BP, smoking, HbA1C, etc) among mild stroke/TIA patients at 12 months post discharge.


#### Secondary Aims

1. Comparison of secondary stroke events

2. Analyze the independent contributions of Risk Perception, Adherence, Patient Physician Communication to primary outcomes.

PI Bernadette Boden-Albala P50 NS049060 (P2)





DESERVE is an innovative patient-paced, multilevel behavioral discharge intervention aimed at secondary stroke prevention through risk factor reduction in 800 mild stroke/TIA patients.

307 patients enrolled from NYU, Mount Sinai and Columbia.

#### **Inclusion Criteria**

- Mild Stroke & TIA patients (consentable without waiver)
- NIHSS <u><</u> 5
- Vascular Risk Factors; including: Hypertension; Smoking ; Metabolic Syndrome

#### **Exclusion Criteria**


- Unable to consent
- Resides or discharged to skilled nursing facility
- Poor survival odds over the study course (12 months)

# **ARTSS-2:** Phase IIb, randomized, multi-center trial of Argatroban in combination with recombinant tissue plasminogen activator for acute stroke

- Andrew Barreto, MD MS, Co-PI
- James Grotta, MD, Co-PI

StrokeNet

- Gary Ford, MD, UK Chief Investigator
- Mohammad H. Rahbar, PhD, PI Data Coordinating Center
- Argatroban Direct Thrombin Inhibitor
- ARTSS-1 Stroke 2012, 43:770-775
  - 0.9mg/kg tPA + low-dose Argatroban × 48 hours
  - Three sICH (4.6%); Total study n=65
  - 40% complete recanalization of proximal intracranial occlusions at 2-hours (13% historical controls with t-PA-alone)



## **ARTSS-2**

- Major inclusion criteria
  - **0-4.5 hour tPA**-treated patients (following ECASS-3 exclusions)
  - Age ≥ 18 (no upper limit)
  - NIHSS ≥10
    - Or any NIHSS if clot demonstrated in proximal intracranial artery
  - INR ≤ 1.5
  - PTT within lab normal range
  - mRS <2
  - No endovascular therapy

- Randomized to 1of 3 treatment arms (n=35 each):
  - 1) Low-dose Argatroban will receive:
    - 100 μg/kg bolus then continuous infusion of 1.0 μg/kg/min for 48 hrs.
       Target aPTT of 1.75 x baseline
  - 2) High-dose Argatroban will receive:
  - 100 μg/kg bolus then continuous infusion of 3.0 μg/kg/min for 48 hrs.
     <u>Target aPTT of 2.25 x baseline</u>
  - 3) Intravenous-rt-PA alone
- Behind Recruitment
  - Many sites are underperforming
  - At current rate, study will complete in 1<sup>st</sup>-2<sup>nd</sup> Quarter 2015
  - We are very open to [a small handful] of motivated centers who would like to join the study



# **MR WITNESS**


#### **Inclusion/Exclusion Summary**

- 80 adult subjects age 18-85 with acute ischemic stroke
- Treatment with IV tPA between 4.5 h to 24 h since Last Known Well (LKW), and within 3 hr of symptom discovery
- Ineligible for on-label rt-PA
- Clinically disabling symptoms and an NIH Stroke Scale score of <=25</li>
- Otherwise eligible to receive rt-PA using usual clinical criteria (except time)
- No contraindications to MRI
- Admission MRI:
  - DWI Positive but FLAIR-negative or faintly positive (defined as a mean signal intensity ratio of 1.15 compared to FLAIR lesion less than 15% of normal tissue.
  - No evidence of CAA

#### Safety Outcomes

- **Primary Outcome**: No significant increase in symptomatic intracranial hemorrhage rates c/w ECASS 3 (rate 5.3%; 95%CI: 3.3-7.9%) with predefined stopping rules
- Secondary Outcome: No significant increase in symptomatic brain edema with mass effect as the predominant cause of clinical deterioration c/w ECASS3 (rate 6.9%; 95%CI: 4.6–10.1%)





# MR WITNESS: Study Progress

- 43/80 (54%) subjects enrolled at 5 sites
  - MGH, NINDS, UT Seton, WUSTL, UCLA, Cedar-Sinai
  - Seeking to add 5-10 additional sites (5 of these contracts pending)
- DSMB has met 3 times and there are no safety concerns
- Interested sites should contact Lee Schwamm (<u>lschwamm@mgh.harvard.edu</u>)
- clinicaltrials.gov/NCT01282242



## **NeuSTART - Phase 2**

- PI: Mitch Elkind, Columbia University
- NIH/NINDS P50 NS049060 (Marshall)
- Contact: mse13@columbia.edu
- **Hypothesis**: Short-term ultra-high-dose statin therapy is feasible and safe in patients with acute ischemic stroke.
- **Primary Aim:** Determine whether lovastatin 640 mg daily for 3 days beginning within 24 hours after acute stroke can be administered **safely**.
- Secondary Aim: Assess efficacy of lovastatin administered at high doses.



# **NeuSTART 2: Key Points**

Key Inclusion criteria:

- ISCHEMIC STROKE WITHIN 24 hrs
- AGE ≥18
- NIHSS ≥2
- IV/IA rt-PA allowed
- No history of significant liver or muscle disease

**Primary outcome**: Liver or muscle complications

Secondary outcomes: Barthel and mRS at 90 days

Sites: Columbia, BWH-Partners (Feske), Univ Miami (Romano), Mount Sinai (Dhamoon), UCLA (Starkman)

Progress to date: 80 patients enrolled; looking for 80 more

Advantages: 1. Includes patients who would may not be eligible for other acute trials. we are Looking for additional sites! Contact: Mitch Elkind: mse13@columbia.edu



### ICTuS 2

- Investigational intervention:
- Endovascular hypothermia to 33°C, followed by rewarming over 12 hours to 36.5°C Group 1, best medical therapy with normothermia (Group 2). randomization: 1:1
- Study Population:
- Acute Ischemic Stroke, treated with IV tPA < 3hours, age 22-82, NIHSS 7-20 (left), 7-24 (right hemisphere)
- Primary aims of the trial:
- To determine whether the combination of intravenous thrombolysis and hypothermia is superior to thrombolysis and normothermia for the treatment of acute ischemic stroke.
- Status of ICTuS 2 (SPOTRIAS)
- On target to meet SPOTRIAS milestones (safety, feasibility of protocol, feasibility of hypothermia).
- Role of StrokeNET:
- The study will be a Phase 3 pivotal efficacy study that follows a SPOTRIAS funded Phase 2 safety and feasibility trial using the identical protocol. Now that safety and feasibility are established, recruitment though StrokeNet will provide the essential boost to meet final recruitment target.



<ul> <li>Alexian Brothers, IL</li> <li>Abington Memorial, PA</li> <li>CHUV, Lausanne Switzerland</li> <li>Colorado Neurological, CO</li> <li>Columbia University, NY*</li> </ul>	<ul> <li>Lee Memorial-Gulf Coast, FL</li> <li>UT Southwestern, Dallas-TX</li> <li>University of Toledo, OH</li> <li>Henry Ford, MI*</li> </ul>
<ul> <li>Cedars Sinai, CA*</li> <li>University of Colorado, CO</li> <li>Hartford Hospital, CT</li> <li>UCSD, CA*</li> <li>Scripps Mercy Hospital, CA*</li> <li>Michigan State Univ, MI</li> <li>North Memorial, MN</li> <li>Sarasota Memorial, FL</li> <li>University of Florida, FL</li> <li>University of Miami, FL*</li> <li>UT Houston, TX*</li> <li>Yale University, CT</li> </ul>	<ul> <li>University of Louisville, KY</li> <li>Intermountain System, UT</li> <li>Baylor University, Dallas-TX</li> <li>Lehigh Valley Hospital, PA</li> <li>Ochsner Clinic, New Orleans-LA</li> <li>Medical College of Wisconsin*</li> </ul>


SPOTRIAS

**CEDARS-S** 

NAL



#### Total Enrollment by Site (as of 05/27/14)





# NCC Staff Change and Opportunity

- Laura Sauerbeck is retiring for family reasons.
- Judy Spilker will be assuming Laura's role but Judy's position is now open. Opening of position both internally and externally.
- The new posting for the pending vacancy within the NCC StrokeNet team is entitled **CLINICAL RESEARCH ADMINISTRATOR/DIRECTOR**.
- If interested in applying, please visit <u>www.jobsatuc.com</u>
  - Upper left hand side of the screen, you'll see SEARCH POSTINGS. Click there.
  - Type 214CM8310 in the field Position Number
  - Click SEARCH.
- Also can contact Rose Beckman for further information.

